Susol O, Susolova B, Klempir O, Navratil M, Gumulec J, Koristek Z
Cancer Med. 2024; 13(24):e70503.
PMID: 39711119
PMC: 11664122.
DOI: 10.1002/cam4.70503.
Rodriguez-Mora S, Corona M, Solera Sainero M, Mateos E, Torres M, Sanchez-Menendez C
Cancers (Basel). 2023; 15(20).
PMID: 37894433
PMC: 10604981.
DOI: 10.3390/cancers15205066.
Donhauser L, Veloso de Oliveira J, Schick C, Manlik W, Styblova S, Lutzenberger S
J Immunother Cancer. 2023; 11(9).
PMID: 37730271
PMC: 10510941.
DOI: 10.1136/jitc-2023-007387.
Yu T, Li W, Yu T
Front Oncol. 2023; 13:1217023.
PMID: 37601670
PMC: 10438954.
DOI: 10.3389/fonc.2023.1217023.
Arbore D, Galdean S, Dima D, Rus I, Kegyes D, Ababei R
J Pers Med. 2022; 12(11).
PMID: 36573722
PMC: 9699250.
DOI: 10.3390/jpm12111886.
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
Uaprasert N, Pitakkitnukun P, Tangcheewinsirikul N, Chiasakul T, Rojnuckarin P
Blood Cancer J. 2022; 12(12):173.
PMID: 36550105
PMC: 9780106.
DOI: 10.1038/s41408-022-00776-5.
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Cook L, ODell G, Vourvou E, Palanicawandar R, Marks S, Milojkovic D
Nat Commun. 2022; 13(1):6922.
PMID: 36376307
PMC: 9662771.
DOI: 10.1038/s41467-022-34657-z.
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper.
Bouza E, Martin M, Ales J, Aragones N, Barragan B, de la Camara R
Rev Esp Quimioter. 2022; 36(1):1-25.
PMID: 36322133
PMC: 9910677.
DOI: 10.37201/req/087.2022.
Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase.
Yilmaz U, Kucukyurt S, Tunc S, Eskazan A
Front Oncol. 2022; 12:994101.
PMID: 36276065
PMC: 9582848.
DOI: 10.3389/fonc.2022.994101.
Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study.
Katagiri S, Akahane D, Otsuki S, Suto A, Yamada A, Suguro T
Vaccines (Basel). 2022; 10(9).
PMID: 36146482
PMC: 9501552.
DOI: 10.3390/vaccines10091404.
Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis.
Rinaldi I, Pratama S, Wiyono L, Tandaju J, Wardhana I, Winston K
Front Oncol. 2022; 12:951215.
PMID: 36003763
PMC: 9393790.
DOI: 10.3389/fonc.2022.951215.
Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
Pascale S, Nuccorini R, Pierri T, Di Mare R, Fabio L, Lerose E
Front Immunol. 2022; 13:892331.
PMID: 36003404
PMC: 9393554.
DOI: 10.3389/fimmu.2022.892331.
[Experts' consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases in China (2022)].
Zhonghua Xue Ye Xue Za Zhi. 2022; 43(5):359-364.
PMID: 35680591
PMC: 9250963.
DOI: 10.3760/cma.j.issn.0253-2727.2022.05.002.
Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.
Rotterdam J, Thiaucourt M, Weiss C, Schwaab J, Reiter A, Kreil S
Ann Hematol. 2022; 101(8):1825-1834.
PMID: 35597847
PMC: 9124009.
DOI: 10.1007/s00277-022-04866-z.
